Related Experiment Video

Updated: Jul 3, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression

Edward Chu

    Clinical Colorectal Cancer
    |July 16, 2008
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
    07:36

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

    Published on: May 16, 2020

    Related Experiment Videos

    Last Updated: Jul 3, 2026

    Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
    07:59

    Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

    Published on: September 8, 2023

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
    07:36

    Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

    Published on: May 16, 2020

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    CDK9 inhibition sensitizes intrinsically resistant BRAF V600E mutant colorectal cancer to BRAF inhibitors.

    Acta pharmaceutica Sinica. B·2026

    High-throughput screening for novel drug combinations using patient-derived organoids.

    Biochemical pharmacology·2026

    High-throughput screening identifies NT-1 that synergizes with MRTX1133 against acquired resistant KRASG12D colorectal cancer.

    NPJ precision oncology·2026

    Artificial Intelligence Chatbots and Their Responses to Most Searched Spanish Cancer Questions.

    Cancer medicine·2025

    Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938).

    Cancer·2025

    Targeting YES1 enhances the efficacy of chemotherapy, targeted therapy and onco-immunotherapy.

    Cellular signalling·2025

    Application of a Domestic Chinese Robotic Surgical System in Radical Resection Combined With Lateral Lymph Node Dissection for Low Rectal Cancer: A Retrospective Study.

    Clinical colorectal cancer·2026

    Colorectal Cancer Screening at Younger Ages: A Multicutoff Analysis of FIT Performance.

    Clinical colorectal cancer·2026

    Neoadjuvant Bevacizumab and Chemoradiotherapy for Locally Advanced Rectal Cancer: Long-Term Outcomes of a Multicentre Study.

    Clinical colorectal cancer·2026

    The Impact of Lesion Morphology and Resection Strategy on Curative Outcomes in Colorectal Malignant Polyps.

    Clinical colorectal cancer·2026

    Comparing Quality of Life in Rectal Cancer Survivors Managed With Watch-and-Wait Versus Surgery.

    Clinical colorectal cancer·2026

    Resource Use and Costs of the Low-risk Arm of a Risk-stratified Colorectal Cancer Screening Approach Based on Previous Negative FIT Values: Comparative Analyses With the Standard Approach.

    Clinical colorectal cancer·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us